Tardive dyskinesia in geriatric patients

Aging Health

Volumn 2, Issue 5, 2006, Pages 833-849

  Ragheb, Moataz M ^a,b   Goldberg, Richard J ^a,c  

^a RHODE ISLAND HOSPITAL   (United States)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c BROWN UNIVERSITY   (United States)

Author keywords

Antipsychotic adverse effects; Elderly movement disorder; Geriatric psychiatry; Tardive dyskinesia

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA TOCOPHEROL; ANTIOXIDANT; ATYPICAL ANTIPSYCHOTIC AGENT; BRANCHED CHAIN AMINO ACID; CATECHOLAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DONEPEZIL; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FREE RADICAL; HALOPERIDOL; LITHIUM; MELATONIN; N TERT BUTYL ALPHA PHENYLNITRONE; NEUROLEPTIC AGENT; PLACEBO; PYRIDOXINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 6 RECEPTOR; UNINDEXED DRUG;

AGE; AGED; AKATHISIA; ANGER; CHOREA; CLINICAL FEATURE; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FALLING; GENETIC ASSOCIATION; GERIATRIC CARE; GUILT; HUMAN; HUNTINGTON CHOREA; HYPERTHYROIDISM; HYPOPARATHYROIDISM; INCIDENCE; INVOLUNTARY MOVEMENT; LABORATORY TEST; MENTAL DISEASE; MYOCLONUS; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NONHUMAN; ORGANIC BRAIN SYNDROME; PHYSICAL EXAMINATION; RESPIRATORY DISTRESS; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEX DIFFERENCE; SPASMODIC TORTICOLLIS; SPEECH DISORDER; STROKE; TARDIVE DYSKINESIA; TIC; TREATMENT DURATION; TREMOR;

EID: 33751016053     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.2.5.833     Document Type: Review

References (191)

1. Lehman AF, Lieberman JF, Dixon LB et al.: Practice guideline for the treatment of patients with schizophrenia. In: Practice Guidelines for Mental Disorders. AP, Association, Arlington, VA, USA (2004).
2. Kruse W: Persistent muscular restlessness after phenothiazine treatment: report of 3 cases. Am. J. Psychiatry 117, 152-153 (1960).
3. American Psychiatric Association Task Force on Tardive Dyskinesia: Tardive Dyskinesia: a task Force Report of the American Psychiatric Association. American Psychiatric Publishing, Washington, DC, USA (1992).
4. Bronskill SE, Anderson GM, Sykora K et al.: Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J. Am. Geriatr. Soc. 52(5), 749-755 (2004).
5. Colenda CC, Mickus MA, Marcus SC et al.: Comparison of adult and geriatric psychiatric practice patterns: findings from the American Psychiatric Association's Practice Research Network. Am. J. Geriatr. Psyrhiatry 10(5), 609-617 (2002).
6. Giron MS, Forsell Y, Bernsten C, Thorslund M, Winblad B, Fastbom J: Psychotropic drug use in elderly people with and without dementia. Int. J. Geriatr. Psychiatry 16(9), 900-906 (2001).
7. Harrington C, Tompkins C, Curtis M, Grant L: Psychotropic drug use in long-term care facilities: a review of the literature. Gerontologist 32(6), 822-833 (1992).
8. Yassa R, Nair NP: A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr. Scand. 86(4), 262-266 (1992).
9. Yassa R, Nastase C, Dupont D, Thibeau M: Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am. J. Psychiatry 149(9), 1206-1211 (1992).
10. Gureje O: The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors. Psychol. Med. 19(1), 121-128 (1989).
11. Jankovic J: Tardive syndromes and other drug-induced movement disorders. Clin. Neuropharmacol. 18(3), 197-214 (1995).
12. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD: The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 121 (Pt 11). 2053-2066 (1998).
13. Barnes TR: Tardive dyskinesia. Br. Med. J. (Clin. Res. Ed.) 296(6616), 150-151 (1988).
14. Kane JM, Woerner M, Lieberman J: Tardive dyskinesia: prevalence, incidence, and risk factors. J. Clin. Psychopharmacol. 8(Suppl. 4), 52S-56S (1988).
15. Chouinard G, Annable L, Ross-Chouinard A, Mercier P: A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of. new cases. J. Clin. Psychopharmacol. 8(4 Suppl.), 21S-26S (1988).
16. Burke RE, Fahn S, Jankovic J et al.: Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 32(12), 1335-1346 (1982).
17. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curacao Extrapyramidal Syndromes Study II. Schizophr. Res. 26(2-3), 235-242 (1997).
18. Van Harten PN, Kahn RS: Tardive dystonia. Schizophr. Bull. 25(4). 741-748 (1999).
19. van Harten PN, Matroos GE, Hoek HW, Kahn RS: The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Curacao Extrapyramidal Syndromes Study: I. Schizophr. Res. 19(2-3), 195-203 (1996).
20. Tan KJ, Jankovic J: Tardive and idiopathic oromandibular dystonia: a clinical comparison. J. Neurol. Neurosurg. Psychiatry 68(2), 186-190 (2000).
21. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD: The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 121(Pt 11), 2053-2066 (1998).
22. Trottenberg T, Volkmann J, Deuschl G et al.: Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology 64(2), 344-346 (2005).
23. Barnes TR: The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatr. Dev. 5(4), 301-319 (1987).
24. Barnes TR, Braude WM: Akathisia variants and tardive dyskinesia. Arch. Gen. Psychiatry 42(9), 874-878 (1985).
25. Kim JH, Jin YH, Kang UG, Ahn YM, Ha KS, Kim YS: Neuroleptic-induced acute and chronic akathisia: a clinical comparison. Mov Disord 20(12), 1667-1670 (2005).
26. Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G: Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia. Schizophr. Res. 77(2-3), 119-128 (2005).
27. Munetz MR, Schulz SC: Screening for tardive dyskinesia. J. Clin. Psychiatry 47(2), 75-77 (1986).
28. Klawans HL, Barr A: Prevalence of spontaneous lingual-facial-buccal dyskinesias in the elderly. Neurology 32(5), 558-559 (1982).
29. Hyde TM, Hotson JR, Kleinman JE: Differential diagnosis of choreiform tardive dyskinesia. J. Neuropsychiatry Clin. Neurosci. 3(3), 255-268 (1991).
30. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 39(4), 486-487 (1982).
31. Goldberg RJ: Tardive dyskinesia in elderly patients: an update. J. Am. Med. Dir. Assoc. 4(Suppl. 2), S32-S42 (2003).
32. Chatterjee A, Chakos M, Koreen A et al.: Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am. J. Psychiatry 152(12), 1724-1729 (1995).
33. Fenton WS, Blyler CR, Wyatt RJ, McGlashan TH: Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br. J. Psychiatry 171, 265-268 (1997).
34. Blanchet PJ, Abdillahi O, Beauvais C, Rompre PH, Lavigne GJ: Prevalence of spontaneous oral dyskinesia in the elderly: a reappraisal. Mov. Disord. 19(8), 892-896 (2004).
35. Bourgeois M, Bouilh P, Tignol J, Yesavage J: Spontaneous dyskinesias vs. neuroleptic-induced dyskinesias in 270 elderly subjects. J. Nerv. Ment. Dis. 168(3), 177-178 (1980).
36. Fenton WS: Prevalence of spontaneous dyskinesia in schizophrenia. J. Clin. Psychiatry 61(Suppl. 4), 10-14 (2000).
37. Bergamo M, Abilio VC, Queiroz CM, Barbosa-Junlor HN, Abdanur LR, Frussa-Filho R: Effects of age on a new animal model of tardive dyskinesia. Neurobiol. Aging 18(6), 623-629 (1997).
38. Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN: Factors related to tardive dyskinesia. Am. J. Psychiatry 136(1), 79-82 (1979).
39. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J: Conventional vs. newer antipsychotics in elderly patients. Am. J. Geriatr. Psychiatry 7(1), 70-76 (1999).
40. de Jesus Mari J, Lima MS, Costa AN et al.: The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur. Arch. Psychiatry Clin. Neurosci. 254(6), 356-361 (2004).
41. Kane JM, Smith JM: Tardive dyskinesia: prevalence and risk factors, 1959 to 1982. Arch. Gen. Psychiatry 39(4), 473-481 (1979).
42. Smith JM, Baldessarini RJ: Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch. Gen. Psychiatry 37(12), 1368-1373 (1980).
43. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM: Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am. J. Psychiatry 155(11), 1521-1528 (1998).
44. Jeste DV, Caligiuri MP, Paulsen JS et al.: Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch. Gen. Psychiatry 52(9), 756-765 (1995).
45. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA: Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am. J. Psychiatry 157(7), 1150-1155 (2000).
46. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP: Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J. Am. Geriatr. Soc. 47(6), 716-719 (1999).
47. Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA: An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr. Res. 77(2-3), 129-139 (2005).
48. Bhanji NH, Margolese HC: Tardive dyskinesia associated with olanzapine in a neuroleptic-naive patient with schizophrenia. Can. J. Psychiatry 49(5), 343 (2004).
49. Woods SW: Olanzapine and tardive dyskinesia. Br. J. Psychiatry 175, 391-392 (1999).
50. Dalack GW, Becks L, Meador-Woodruff JH: Tardive dyskinesia, clozapine, and treatment response. Prog. Neuropsychopharmacol. Biol. Psychiatry 22(4), 567-573 (1998).
51. Mendhekar DN: Ziprasidone-induced tardive dyskinesia. Can. J. Psychiatry 50(9), 567-568 (2005).
52. Beasley CM. Dellva MA, Tamura RN: Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br. J. Psychiatry 174, 23-30 (1999).
53. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry 154(9), 1248-1254 (1997).
54. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP: Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am. J. Pychiatry 156(2), 309-311 (1999).
55. Lee PE, Sykora K, Gill SS: Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a poputation-based cohort study in older adults. J. Am. Geriatr. Soc. 53(8), 1374-1379 (2005).
56. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Pychiatry 161(3), 414-425 (2004).
57. Trosch RM: Neuroleptic-induced movement disorders: deconstructing extrapyramidal symptoms. J. Am. Geriatr. Soc. 52(12 Suppl.), S266-S271 (2004).
58. Casey DE: Tardive dyskinesla and atypical antipsychotic drugs. Schizophr. Res. 35(Suppl.), S61-S66 (1999).
59. Egan MF, Apud J, Wyatt RJ: Treatment of tardive dyskinesia. Schizophr. Bull. 23(4), 583-609 (1997).
60. Yassa R, Jeste DV: Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr. Bull. 18(4), 701-715 (1992).
61. Waddington JL, O'Callaghan E, Buckley P et al.: Tardive dyskinesia in schizophrenia. Relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on magnetic resonance imaging. Br. J. Psychiatry 167(1), 41-44 (1995).
62. Waddington JL: Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. Int. Rev. Neurobiol. 31, 297-353 (1989).
63. Akbostanci MC, Atbasoglu EC, Balaban H: Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution. Acta Neurol. Belg. 99(3), 176-181 (1999).
64. Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P: Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J. Clin. Psychopharmacol. 19(3), 203-208 (1999).
65. Saltz BL, Woerner MG, Kane JM: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266(17). 2402-2406 (1991).
66. Glazer WM, Morgenstern H, Doucette JT: The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study Br. J. Psychiatry 158, 822-828 (1991).
67. Glazer WM, Morgenstern H. Schooler N, Berkman CS, Moore DC: Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br. J. Psychiatry 157, 585-592 (1990).
68. Yassa R, Nair V, Schwartz G: Early versus late onset psychosis and tardive dyskinesia. Biol. Psychiatry 21(13), 1291-1297 (1986).
69. Harris MJ, Panton D, Caligiuri MP et al.: High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Psychopharmacol. Bull. 28(1), 87-92 (1992).
70. Roth GS: Changes in tissue responsiveness to hormones and neurotransmitters during aging. Exp. Gerontol. 30(3-4), 361-368 (1995).
71. Durnas C, Loi CM, Cusack BJ: Hepatic drug metabolism and aging. Clin. Pharmacokinet. 19(5), 359-389 (1990).
72. Jeste DV, Karson CN, Iager AC, Bigelow LB. Wyatt RJ: Association of abnormal involuntary movements and negative symptoms. Pychopharmacol. Bull. 20(3), 380-381 (1984).
73. Liddle PF, Barnes TR, Speller J, Kibel D: Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia. Br. J. Rychiatry 163, 776-780 (1993).
74. Barnes TR, Liddle PF, Curson DA, Patel M: Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia. Br. J. Pychiatry 7(Suppl.), 99-103 (1989).
75. Casey DE: Affective disorders and tardive dyskinesia. Encephale 14, 221-226 (1988).
76. Kane JML: Tardive dyskinesia in affective disorders. J. Clin. Psychiatry 60(Suppl. 5), 43-47 (1999).
77. Schulze TG, Muller DJ, Krauss H et al.: Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia? Eur. Psychiatry 16(1), 71-74 (2001).
78. Richardson MA, Pass R, Bregman Z, Craig TJ: Tardive dyskinesia and depressive symptoms in schizophrenics. Psychopharmacol. Bull. 21(1), 130-135 (1985).
79. Wegner JT, Catalano F, Gibralter J et al.: Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology. Arch. Gen. Psychiatry 42(9), 860-865 (1985).
80. Yassa R, Neelakanta PV, Nair et al.: Factors in the development of severe forms of tardive dyskinesia. Am. J. Psychiatry 147(9), 1156-1163 (1990).
81. Ohmori O, Shinkai T, Hori H et al.: A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy. Prog. Neurosychopharmacol. Biol. Psychiatry 27(4), 581-586 (2003).
82. Arthur H, Dahl ML, Siwers B et al.: Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J. Clin. Psychopharmacol. 15(3), 211-216 (1995).
83. Tiwari AK, Deshpande SN, Rao AR et al.: Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subject: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr. Res. 75(1), 21-26 (2005).
84. Matsumoto C, Ohmori O, Shinkai T et al: Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr. Genet. 14(4), 209-213 (2004).
85. Liou YJ, Liao DL, Chen JY et al.: Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med. 5(3), 243-251 (2004).
86. Woo SI, Kim JW, Rha E et al: Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin. Neurosci. 56(4), 469-474 (2002).
87. Garcia-Barcelo MM, Lam LC, Ungvari GS et al.: Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm. 108(6), 671-677 (2001).
88. Herken H, Erdal ME, Boke O et al.: Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-O-methyltransferase gene. Eur. Psychiatry 18(2), 77-81 (2003).
89. Zhang ZJ, Zhang XB, Sha WW et al.: Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol. Psychiatry 7(7), 670-671 (2002).
90. Basile VS, Ozdemir V, Masellis M et al.: Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol. Psychiatry 6(2), 230-234 (2001).
91. Ohmori O, Shinkai T, Hori H et al.: Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia. Psychiatry Res. 110(2), 97-102 (2002).
92. Segman RH, Heresco-Levy U, Finkel B et al.: Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl.) 152(4), 408-413 (2000).
93. Halford J. Mazeika G, Slifer S et al.: APOE2 allele increased in tardive dyskinesia. Mov. Disord. 21(4), 540-542 (2006).
94. Steen VM, Lovlie R, MacEwan T et al.: Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry 2(2), 139-145 (1997).
95. Lerer B, Segman RH, Fangerau H et al.: Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27(1), 105-119 (2002).
96. Inada T, Dobashi I, Sugita T et al.: Search for a susceptibility locus to tardive dyskinesia. Hum. Psychopharmacology 12 (1), 35-39 (1997).
97. Lovlie R, Daly AK, Blennerhassett R et al.: Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. Int. J. Neuropsychopharmacol. 3(1), 61-65 (2000).
98. Rietschel M. Krauss H, Muller DJ et al.: Dopamine D3 receptor variant and tardive dyskinesia. Eur. Arch. Psychiatry Clin. Neurosci. 250(1), 31-35 (2000).
99. Caligiuri MP, Lacro JP, Rockwell E et al.: Incidence and risk factors for severe tardive dyskinesia in older patients. Br. J. Psychiatry 171, 148-153 (1997).
100. Oosthuizen PP, Emsley RA, Maritz JS: Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J. Clin. Psychiatry 64(9), 1057-1080 (2003).
101. Richelson E: Preclinical pharmacology of neuroleptics: focus on new generation compounds. J. Clin. Psychiatry 57(Suppl. 11), 4-11 (1996).
102. Klawans H Jr, Ilahi MM, Shenker D: Theoretical implications of the use of L-dopa in parkinsonism. A review. Acta Neurol. Scand. 46(4), 409-441 (1970).
103. Tamminga CA, Thaker GK, Chase TN: GABA dysfunction in the pathophysiology of tardive dyskinesia. Psychopharmacology 2(Suppl.), 122-127 (1985).
104. Tamminga CA, Thaker GK, Nguyen JA: GABAmimetic treatments for tardive dyskinesia: efficacy and mechanism. Psychopharmacol. Bull. 25(1), 43-46 (1989).
105. Anderson U, Haggstrom, JE, Levin ED et al.: Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia. Mov. Disord. 4(1), 37-46 (1989).
106. Pai BN, Janakiramaiah N, Gangadhar BN et al.: Depletion of glutathlone and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol. Psychiatry 36(7), 489-491 (1994).
107. Henry B, Duty S, Fox SH et al.: Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neuvol. 183(2), 458-468 (2003).
108. Crossman AR: A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov. Disord. 5(2), 100-108 (1990).
109. Turrone P, Remington G, Nobrega JN: The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci. Biobehav. Rev. 26(3), 361-380 (2002).
110. Adler CM, Malhotra AK, Elman I et al.: Amphetamine-induced dopamine release and post-synaptic specific binding in patients with mild tardive dyskinesia. Neuropsychopharmacology 26(3), 295-300 (2002).
111. Hori H, Ohmori O, Shinkai T et al.: Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet. 105(8), 774-778 (2001).
112. Blin J, Baron JC, Cambon H et al.: Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J. Neurol. Neursurg. Psychiatry 52(11), 1248-1252 (1989).
113. Andersson U, Eckernas SA, Hartvig P et al.: Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding. J. Neurol Transm. Gen. Sect. 79(3), 215-226 (1990).
114. Thaker GK, Tamminga CA, Alphs LD et al.: Brain γ-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Arch. Gen. Psychiatry 44(6), 522-529 (1987).
115. Tamminga CA, Thaker GK, Hare T et al.: GABA agonist treatment improves tardive dyskinesia. Lancet 2(8341), 97-98 (1983).
116. Thaker G, Nguyen J, Strauss M: Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am. J. Psychiatry 147(4), 445-451 (1990).
117. Faria RR, Abilio VC, Grassl C et al.: Beneficial effects of vitamin C and vitamin E on reserpine-induced oral dyskinesia in rats: critical role of striatal catalase activity. Neuropharmacology 48(7), 993-1001 (2005).
118. Rogoza RM, Fairfax DF, Henry P et al.: Electron spin resonance spectroscopy reveals α-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia. Synapse 54(3), 156-163 (2004).
119. Harvey BH, Nel A: Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia. Brain Res. Bull. 61(4), 407-416 (2003).
120. Brown K, Reid A, White T et al.: Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol. Psychiatry 43(12), 863-867 (1998).
121. Peet M, Laugharne J, Rangarajan N et al.: Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int. Clin. Psychopharmacol. 8(3), 151-153 (1993).
122. Lohr JB, Kuczenski R, Niculescu AB: Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17(1), 47-62 (2003).
123. McCreadie RG, Macdonald E, Wiles, D et al.: The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. Br. J. Psychiatry. 167(5), 610-617 (1995).
124. Adler LA, Rotrosen J, Edson R et al.: Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study 394 Study Group. Arch. Gen. Psychiatry 56(9), 836-841 (1999).
125. Bergen JA, Eyland EA, Campbell JA et al.: The course of tardive dyskinesia in patients on long-term neuroleptics. Br. J. Psychiatry 154, 523-528 (1989).
126. Gardos G, Casey DE, Cole JO et al.: The natural history of tardive dyskinesia. J. Clin. Psychopharmacol. 8(4 Suppl.), 31S-37S (1988).
127. Eberhard J, Lindstrom E, Levander S: Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Int. Clin. Psychopharmacol. 21(1), 35-42 (2006).
128. Newell KM, Wszola B, Sprague RL et al.: The changing effector pattern of tardive dyskinesia during the course of neuroleptic withdrawal. Exp. Clin. Psychopharmacol. 9(3), 262-268 (2001).
129. Gardos G, Cole JO, Haskell D et al.: Ten-year outcome of tardive dyskinesia. Am. J. Psychiatry 151(6), 836-841 (1994).
130. Diederich NJ, Goetz CG: Drug-induced movement disorders. Neurol. Clin. 16(1), 125-139 (1998).
131. Ghadirian A, Annable L, Belanger M et al.: A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J. Clin. Psychiatry 57(1), 22-28 (1996).
132. Lazarus A: Tardive dyskinesia-like syndrome associated with lithium and carbamazepine. J. Clin. Psychopharmacol. 14(2), 146-147 (1994).
133. Sachdev P, Saharov T, Cathcart S: The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia. Biol. Pychiatry 16(12), 1672-1681 (1999).
134. Gattaz WF, Emrich A, Behrens S: Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia. J. Neural Transm. Gen. Sect. 92(2-3), 197-201 (1993).
135. Margolese HC, Chouinard G, Kolivakis TT et al.: Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can. J. Psychiatry 50(11), 703-714 (2005).
136. Davidson M, Harvey PD, Vervarcke J et al.: A long-term. multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int. J. Geriatr. Psychiatry 15(6), 506-514 (2000).
137. O'Brien J, Barber R: Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject. Br. J. Psychiatry 172, 186 (1998).
138. Kooptiwoot S, Settachan T: Improvement of tardive dyskinesia with risperidone: a case report. J. Med. Assoc. Thal. 83(11), 1430-1432 (2000).
139. Rangwani SR, Gupta S, Burke WJ et al.: Improvement of debilitating tardive dyskinesia with risperidone. Ann. Clin. Psychiatry 8(1), 27-29 (1996).
140. Chouinard G: Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J. Clin. Psychopharmacol. 15 (1 Suppl. 1), 36S-44S (1995).
141. Emsley R, Turner JH, Schronen J et al.: A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J. Clin. Psychiatry 65(5), 696-701 (2004).
142. Gourzis P, Polychronopoulos P, Papapetroupoulos S et al.: Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases. Clin. Neuropharmacol. 28(4), 195-196 (2005).
143. Bouckaert F, Herman G, Peuskens J: Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine. Int. J. Geriatr. Psychiatry 20(3), 287-288 (2005).
144. Sasaki Y, Kusumi I, Koyama T: A case of tardive dystonia successfully managed with quetiapine. J. Clin. Psychiatry 65(4), 583-584 (2004).
145. Ghelber D, Belmaker RH: Tardive dyskinesia with quetiapine. Am. J. Psychiatry 156(5), 796-797 (1999).
146. Ghaemi SN, Ko JY: Quetiapine-related tardive dyskinesia. Am. J. Psychiatry 158(10), 1737 (2001).
147. Sharma V: Treatment-emergent tardive dyskinesia with quetiapine in mood disorders. J. Clin. Psychopharmacol. 23(4), 415-417 (2003).
148. Grant MJ, Baldessarini RJ: Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann. Pharmacother. 39(11), 1953 (2005).
149. Witschy JK, Winter AS: Improvement in tardive dyskinesia with aripiprazole use. Can. J. Psychiatry 50(3), 188 (2005).
150. Duggal HS: Aripiprazole-induced improvement in tardive dyskinesia. Can. J. Psychiatry 48(11), 771-772 (2003).
151. Papapetropoulos S, Wheeler S, Singer C: Tardive dystonia associated with ziprasidone. Am. J. Psychiatry 162(11), 2191 (2005).
152. Ananth J, Burgoyne KS, Niz D et al.: Tardive dyskinesia in 2 patients treated with ziprasidone. J. Psychiatry Neurosci. 29(6), 467-469 (2004).
153. Keck ME, Muller MB, Binder EB et al.: Ziprasidone-related tardive dyskinesia. Am. J. Psychiatry 161(1), 175-176 (2004).
154. Sajatovic M, Jaskiw G, Konicki PE et al.: Outcome of clozapine therapy for elderly patients with refractory primary psychosis. Int. J. Geriatr. Psychiatry 12(5), 553-558 (1997).
155. Sweet RA, Pollock BG: New atypical antipsychotics. Experience and utility in the elderly. Drugs Aging 12(2), 115-127 (1998).
156. Barak Y, Wittenberg N, Naor S et al.: Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr. Psychiatry 40(4), 320-325 (1999).
157. Jeste DV, Wyatt RJ: In search of treatment for tardive dyskinesia: review of the literature. Schizophr. Bull. 5(2), 251-293 (1979).
158. Glazer WM, Hafez H: A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr. Res. 3(5-6), 315-320 (1990).
159. Caine ED, Polinsky RJ, Kartzinel R et al.: The trial use of clozapine for abnormal involuntary movement disorders. Am. J. Psychiatry 136(3), 317-320 (1979).
160. Lieberman J, Lesser M, Johns C et al.: Pharmacologic studies of tardive dyskinesia. J. Clin. Psychopharmacol. 8 (4 Suppl.), 57S-63S (1988).
161. Jeste DV, Lohr JB, Clark K: Pharmacological treatments of tardive dyskinesia in the 1980s. J. Clin. Psychopharmacol. 8 (Suppl. 4). 38S-48S (1988).
162. Tarsy D, Kaufman D, Sethi KD et al.: An open-label study of botulinum toxin for treatment of tardive dystonia. Clin. Neuropharmacol. 20(1), 90-93 (1997).
163. Soares-Weiser KV, Joy C: Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. (2), CD000208 (2003).
164. Richardson MA, Bevans ML, Read LL et al.: Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am. J. Psychiatry 160(6), 1117-1124 (2003).
165. Mouret J, Khomais M, Lemoine P et al.: Low-dose insulin as a treatment of tardive dyskinesia: conjuncture or conjecture? Eur. Neurol. 31(4), 199-203 (1991).
166. Gelenberg AJ, Dorer DJ, Wojcik JD et al.: A crossover study of lecithin treatment of tardive dyskinesia. J. Clin. Psychiatry 51(4), 149-153 (1990).
167. Gelenberg AJ, Doller-Wojcik JC, Growdon JH: Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am. J. Psychiatry 136(6), 772-776 (1979).
168. Miller R, Chouinard G: Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry 34(10), 713-738 (1993).
169. Caroff SN, Campbell EC, Havey J et al.: Treatment of tardive dyskinesia with donepezil: a pilot study. J. Clin. Psychiatry 62(10), 772-775 (2001).
170. Angus S, Sugars J, Boltezar R et al.: A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J. Clin. Psychopharmacol. 17(2), 88-91 (1997).
171. Ludatscher JI: Stable remission of tardive dyskinesia by L-dopa. J. Clin. Psychopharmacol. 9(1), 39-41 (1989).
172. Nelson LA, McGuire JM, Hausafus SN: Melatonin for the treatment of tardive dyskinesia. Ann. Pharmacother. 37(7-8), 1128-1131 (2003).
173. Shamir E, Barak Y, Plopsky I et al.: Is melatonin treatment effective for tardive dyskinesia? J. Clin. Psychiatry 61(8), 556-558 (2000).
174. Shamir E, Barak Y, Shalman I et al.: Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch. Gen. Psychiatry 58(11), 1049-1052 (2001).
175. Sirota P, Mosheva T, Hertzel S et al.: Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am. J. Psychiatry 157(2), 287-289 (2000).
176. Ondo WG, Hanna PA, Jankovic J: Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am. J. Psychiatry 156(8), 1279-1281 (1999).
177. Lerner V, Miodownik C, Kapstan A et al.: Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am. J. Psychiatry 158(9), 1511-1514 (2001).
178. Barak Y, Swartz M, Shamir E et al.: Vitamin E (α-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann. Clin. Pychiapy 10(3), 101-105 (1998).
179. Adler LA, Peselow E, Rotrosen J et al.: Vitamin E treatment of tardive dyskinesia. Am. J Psychiatry 150(9), 1405-1407 (1993).
180. Ellingrod VL, Schultz SK, Ekstam-Smith K et al.: Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy 22(1), 1-5 (2002).
181. Yaffe K, Fox P, Newcomer R et al.: Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 287(16), 2090-2097 (2002).
182. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293(5), 596-608 (2005).
183. Deberdt WG, Dysken MW, Rappaport SA et al.: Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am. J. Geriatr. Psychiatry 13(8), 722-730 (2005).
184. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294(15), 1934-1943 (2005).
185. Layton D, Harris S, Wilton LV et al.: Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J. Psychopharmacol. 19(5), 473-4782 (2005).
186. Moretti R, Torre P, Antonello RM et al.: Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of
187. Verkaik R, van Weert JC, Francke AL: The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int. J. Geriatr. Psychiatry 20(4), 301-314 (2005).
188. Wang PS, Schneeweiss S, Avorn J et al.: Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med. 353(22), 2335-2341 (2005).
189. Colenda CC, Streim J, Green JA et al.: The impact of OBRA '87 on psychiatric services in nursing homes. Joint testimony of the American Psychiatric Association and the American Association for Geriatric Psychiatry Am. J. Geriatr. Psychiatry 7(1), 12-17 (1999).
190. Fossey J, Ballard C, Juszczak E et al: Effect of enhanced psychological care on antispychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ 332, 756-761 (2006).
191. Cody M, Beck C, Svarstad BL: Challenges to the use of nonpharmacologic interventions in nursing homes. Psychiatr. Serv. 53(11), 1402-1406 (2002).